Safe anticoagulation with danaparoid in pregnancy and lactation

Thromb Haemost 2004; 92(01): 211
DOI: 10.1055/s-0037-1613643

Case Report

Schattauer GmbH

Authors

Marc Schindewolf

¹Division of Vascular Medicine, I. Medical Department, Centre of International Medicine, Johann Wolfgang Goethe-University Hospital, Frankfurt/Main, Germany
Gerlinde Mosch

¹Division of Vascular Medicine, I. Medical Department, Centre of International Medicine, Johann Wolfgang Goethe-University Hospital, Frankfurt/Main, Germany
Rupert M. Bauersachs

¹Division of Vascular Medicine, I. Medical Department, Centre of International Medicine, Johann Wolfgang Goethe-University Hospital, Frankfurt/Main, Germany
Edelgard Lindhoff-Last

¹Division of Vascular Medicine, I. Medical Department, Centre of International Medicine, Johann Wolfgang Goethe-University Hospital, Frankfurt/Main, Germany

References
1 Lindhoff-Last E, Bauersachs R. Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation. Semin Thromb Hemost 2002; 28 (05) 439-46.
2 Greinacher A, Eckhardt T, Mussmann J. et al. Pregnancy complicated by heparin associated thrombocytopenia: management by a prospectively in vitro selected heparinoid (Org 10172). Thromb Res 1993; 71 (02) 123-6.
3 Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1998; 114 (Suppl. 05) 524-530S.
4 Harrison SJ, Rafferty I, McColl MD. Management of heparin allergy during pregnancy with danaparoid. Blood Coagul Fibrinolysis 2001; 12: 157-9.
5 Peeters LL, Hobbelen PM, Verkeste LL. et al. Placental transfer of Org 10172, a low-molecular weight heparinoid, in the awake late-pregnant guinea pig. Thromb Res 1986; 44 (03) 277-83.